Literature DB >> 23846544

Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract.

Anne-Christin Stolt1, Helmut Schröder, Hartmud Neurath, Gisela Grecksch, Volker Höllt, Markus R Meyer, Hans H Maurer, Nancy Ziebolz, Ursula Havemann-Reinecke, Axel Becker.   

Abstract

OBJECTIVE: Mitragyna speciosa and its extracts are named kratom (dried leaves, extract). It contains several alkaloids and is used in traditional medicine to alleviate musculoskeletal pain, hypertension, coughing, diarrhea, and as an opiate substitute for addicts. Abuse and addiction to kratom is described, and kratom has attracted increasing interest in Western countries. Individual effects of kratom on opioidergic, adrenergic, serotonergic, and dopaminergic receptors are known, but not all of the effects have been explained. Pharmacokinetic and pharmacodynamic data are needed.
METHODS: The effects of kratom extract on mice behavior were investigated following oral (po), intraperitoneal (ip), and intracerebroventricular (icv) application. Receptor-binding studies were performed.
RESULTS: In μ opioid receptor knockout mice (-/-) and wild type (+/+) animals, the extract reduced locomotor activity after ip and low po doses in +/+ animals, but not after icv administration. The ip effect was counteracted by 0.3 mg/kg of apomorphine sc, suggesting dopaminergic presynaptic activity. An analgesic effect was only found in -/- mice after icv application. Norbinaltorphimine abolished the analgesic effect, but not the inhibitory effect, on locomotor activity, indicating that the analgesic effect is mediated via κ opioid receptors. Oral doses, which did not diminish locomotor activity, impaired the acquisition of shuttle box avoidance learning. There was no effect on consolidation. Binding studies showed affinity of kratom to μ, δ, and κ opioid receptors and to dopamine D1 receptors.
CONCLUSIONS: The results obtained in drug-naïve mice demonstrate weak behavioral effects mediated via μ and κ opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846544     DOI: 10.1007/s00213-013-3201-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Fast and simple procedure for liquid-liquid extraction of 136 analytes from different drug classes for development of a liquid chromatographic-tandem mass spectrometric quantification method in human blood plasma.

Authors:  Daniela Remane; Markus R Meyer; Frank T Peters; Dirk K Wissenbach; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2010-05-22       Impact factor: 4.142

2.  Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants.

Authors:  Dirk K Wissenbach; Markus R Meyer; Daniela Remane; Armin A Weber; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2010-11-16       Impact factor: 4.142

3.  Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding sites in CB1-expressing HEK 293 cells and rat brain tissue.

Authors:  Helmut Schröder; Volker Höllt; Axel Becker
Journal:  Neurochem Int       Date:  2010-11-10       Impact factor: 3.921

4.  A study of kratom eaters in Thailand.

Authors:  S Suwanlert
Journal:  Bull Narc       Date:  1975 Jul-Sep

5.  The Use of Mitragynine speciosa ("Krathom"), an addictive plant, in Thailand.

Authors:  Sawitri Assanangkornchai; Anocha Muekthong; Nisan Sam-Angsri; Uriwan Pattanasattayawong
Journal:  Subst Use Misuse       Date:  2007       Impact factor: 2.164

6.  A coincidence of addiction to "Kratom" and severe primary hypothyroidism.

Authors:  Sergey V Sheleg; Gregory B Collins
Journal:  J Addict Med       Date:  2011-12       Impact factor: 3.702

7.  Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice.

Authors:  S Thongpradichote; K Matsumoto; M Tohda; H Takayama; N Aimi; S Sakai; H Watanabe
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

8.  Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems.

Authors:  K Matsumoto; M Mizowaki; T Suchitra; Y Murakami; H Takayama; S Sakai; N Aimi; H Watanabe
Journal:  Eur J Pharmacol       Date:  1996-12-12       Impact factor: 4.432

9.  Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors.

Authors:  K Matsumoto; M Mizowaki; T Suchitra; H Takayama; S Sakai; N Aimi; H Watanabe
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

10.  Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry.

Authors:  Anika A Philipp; Dirk K Wissenbach; Siegfried W Zoerntlein; Oliver N Klein; Jidapha Kanogsunthornrat; Hans H Maurer
Journal:  J Mass Spectrom       Date:  2009-08       Impact factor: 1.982

View more
  11 in total

1.  Discriminative stimulus properties of mitragynine (kratom) in rats.

Authors:  Norsyifa Harun; Zurina Hassan; Visweswaran Navaratnam; Sharif M Mansor; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2015-01-25       Impact factor: 4.530

2.  Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey.

Authors:  Rhiannon Bath; Tanner Bucholz; Amy F Buros; Darshan Singh; Kirsten E Smith; Charles A Veltri; Oliver Grundmann
Journal:  J Addict Med       Date:  2020 May/Jun       Impact factor: 4.647

Review 3.  Herbal Highs: Review on Psychoactive Effects and Neuropharmacology.

Authors:  Silvia Graziano; Laura Orsolini; Maria Concetta Rotolo; Roberta Tittarelli; Fabrizio Schifano; Simona Pichini
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

4.  Kratom instrumentalization for severe pain self-treatment resulting in addiction - A case report of acute and chronic subjective effects.

Authors:  Elisabeth Müller; Thomas Hillemacher; Christian P Müller
Journal:  Heliyon       Date:  2020-07-21

Review 5.  Mitragyna speciosa: Clinical, Toxicological Aspects and Analysis in Biological and Non-Biological Samples.

Authors:  Vânia Meireles; Tiago Rosado; Mário Barroso; Sofia Soares; Joana Gonçalves; Ângelo Luís; Débora Caramelo; Ana Y Simão; Nicolás Fernández; Ana Paula Duarte; Eugenia Gallardo
Journal:  Medicines (Basel)       Date:  2019-03-04

Review 6.  Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review.

Authors:  Steven C Eastlack; Elyse M Cornett; Alan D Kaye
Journal:  Pain Ther       Date:  2020-01-28

7.  Kratom policy: The challenge of balancing therapeutic potential with public safety.

Authors:  Walter C Prozialeck; Bonnie A Avery; Edward W Boyer; Oliver Grundmann; Jack E Henningfield; Andrew C Kruegel; Lance R McMahon; Christopher R McCurdy; Marc T Swogger; Charles A Veltri; Darshan Singh
Journal:  Int J Drug Policy       Date:  2019-05-16

Review 8.  A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.

Authors:  Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers
Journal:  Hum Psychopharmacol       Date:  2021-07-26       Impact factor: 2.130

Review 9.  Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries.

Authors:  Eduardo Cinosi; Giovanni Martinotti; Pierluigi Simonato; Darshan Singh; Zsolt Demetrovics; Andres Roman-Urrestarazu; Francesco Saverio Bersani; Balasingam Vicknasingam; Giulia Piazzon; Jih-Heng Li; Wen-Jing Yu; Máté Kapitány-Fövény; Judit Farkas; Massimo Di Giannantonio; Ornella Corazza
Journal:  Biomed Res Int       Date:  2015-11-10       Impact factor: 3.411

10.  Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions.

Authors:  D A Todd; J J Kellogg; E D Wallace; M Khin; L Flores-Bocanegra; R S Tanna; S McIntosh; H A Raja; T N Graf; S E Hemby; M F Paine; N H Oberlies; N B Cech
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.